Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.
Own stocks of companies that get drugs approved. That hasn’t been so easy. But the U.S. Food & Drug Administration (FDA) has ...
High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...
It may be possible to collect nearly three times as many stem cells for sickle cell gene therapy with motixafortide than ...
When Pfizer acquired Global Blood Therapeutics in October 2022, the flagship drug in the company’s portfolio was Oxbryta, a groundbreaking treatment that targets the root cause of sickle cell ...
The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...
Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...
The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback